Asco Annual Meeting News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Asco annual meeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Asco Annual Meeting Today - Breaking & Trending Today

Oncologists Explore Treatment Options in LGSOC, Look Toward Promising Future

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development. ....

United States , Washington University , Davidm Omalley , Premalh Thaker , Shannonn Westin , Onclive News Network , Department Of Obstetrics , Division Of Gynecologic Oncology , Ohio State University College Of Medicine , University Of Texas Md Anderson Cancer Center , Ohio State University Comprehensive Cancer Center , Department Of Gynecologic Oncology , Division Of Surgery , Emerging Therapies , Low Grade Serous Ovarian Cancer , Gynecologic Oncology , Reproductive Medicine , Cancer Center , Lynn Mutch Professor , Washington University School , Ohio State University College , Ovarian Cancer , Gynecologic Cancer , Md Anderson Cancer Center , Nrg Gy019 Trial , University School Of Medicine ,

Enfortumab Vedotin/Pembrolizumab Combo, Maintenance Avelumab Continue as Gold Standards in Metastatic Urothelial Cancer

Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research. ....

United States , Mayo Clinic In Rochester , Powlest Sridhar , Lancec Pagliaro , Department Of Oncology , American Urological Association Annual Meeting , Division Of Medical Oncology , Urological Association Annual , Medical Oncology , Mayo Clinic , Science Summit , Enfortumab Vedotin , Asco Annual Meeting , Fda Approval , Aua Meeting , State Of The Science Summit , Mayo Clinic In ,

FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval. ....

Michael Vasconcelles , European Medicines Agency Acceptance , China National Medical Products Administration , P European Medicines Agency , Immunogen Inc , Prescription Drug User Fee Act , National Medical Products , Mirvetuximab Soravtansine , Ovarian Cancer , Platinum Resistant Ovarian Cancer , Frα Platinum Resistant Ovarian Cancer , Priority Review , Phase 3 Soraya Trial , Phase 3 Marisol Trial , Asco Annual Meeting , Antibody Drug Conjugate ,

Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects. ....

United States , Dana Farber Cancer Institute , Elizabethi Buchbinder , Harvard Medical School , Asco Annual Meeting , Immune Related Adverse Effects ,

ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer

Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future. ....

San Francisco , United States , Denisem Wolf , Michaelj Campbell , Department Of Laboratory Medicine , University Of California , Laboratory Medicine , Cancer Cell , Investigational Device Exemption , Breast Cancer , Asco Annual Meeting ,